G T Grossberg

Summary

Publications

  1. ncbi Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
    George Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, 1438 South Grand Boulevard, St Louis, MO 63104, USA
    Alzheimer Dis Assoc Disord 23:158-64. 2009
  2. ncbi Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
    G T Grossberg
    St Louis University School of Medicine, St Louis, MO, USA
    Int J Clin Pract 64:651-60. 2010
  3. ncbi Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease
    George Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, MO, USA
    Am J Alzheimers Dis Other Demen 26:65-71. 2011
  4. ncbi Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
    G T Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO 63104, USA
    Int J Clin Pract 65:465-71. 2011

Detail Information

Publications4

  1. ncbi Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension
    George Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, 1438 South Grand Boulevard, St Louis, MO 63104, USA
    Alzheimer Dis Assoc Disord 23:158-64. 2009
    ..No unexpected safety issues arose, and skin tolerability was good; similar to the double-blind study. During the 28-week, open-label extension phase, the patch seemed to be well tolerated with a favorable safety profile...
  2. ncbi Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
    G T Grossberg
    St Louis University School of Medicine, St Louis, MO, USA
    Int J Clin Pract 64:651-60. 2010
    ..The rivastigmine patch provides a viable treatment option for patients with mild to moderate AD...
  3. ncbi Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease
    George Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, MO, USA
    Am J Alzheimers Dis Other Demen 26:65-71. 2011
    ..Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD)...
  4. ncbi Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease
    G T Grossberg
    Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO 63104, USA
    Int J Clin Pract 65:465-71. 2011
    ..The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch...